Endocrine resistance in breast cancer: Molecular pathways and rational development of targeted therapies

Future Oncology

Volumn 8, Issue 3, 2012, Pages 273-292

  Roop, Ryan P ^a   Ma, Cynthia X ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

breast cancer; endocrine resistance; growth factor; targeted therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 5 AZA 2' DEOXYCYTIDINE; ANASTROZOLE; BKM 120; DASATINIB; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ESTROGEN; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FULVESTRANT; GANITUMAB; GEFITINIB; LAPATINIB; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MK 2206; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; SELUMETINIB; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; ENDOCRINE RESISTANCE; GENE EXPRESSION; GENE SILENCING; HORMONAL THERAPY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENDOCRINE SYSTEM; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, ESTROGEN;

EID: 84858385940     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.8     Document Type: Review

References (189)

1. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. Selective estrogen receptor modulators: Discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 64(4), 1522-1533 (2004)
2. Nemere I, Pietras RJ, Blackmore PF. Membrane receptors for steroid hormones: Signal transduction and physiological significance. J. Cell. Biochem. 88(3), 438-445 (2003)
3. Osborne CK, Schiff R. Estrogen-receptor biology: Continuing progress and therapeutic implications. J. Clin. Oncol. 23(8), 1616-1622 (2005
4. Acconcia F, Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett. 238(1), 1-14 (2006
5. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 29(14), 2905-2919 (2001
6. Kushner PJ, Agard DA, Greene GL et al. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74(5), 311-317 (2000
7. Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 19(4), 833-842 (2005
8. Kato S, Endoh H, Masuhiro Y et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270(5241), 1491-1494 (1995
9. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: How growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res. 9(1 Pt 2), S447-S454 (2003
10. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res. 10(1 Pt 2), 331S-336S (2004
11. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst. 96(12), 926-935 (2004
12. Wu RC, Smith CL, O'Malley BW. Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr. Rev. 26(3), 393-399 (2005
13. Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15(9), 2174-2183 (1996
14. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9(9), 631-643 (2009
15. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62, 233-247 (2011
16. Saxena R, Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Med. Res. Rev. doi:0.1002/med.20209 (2010) (Epub ahead of print
17. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19(3), 183-232 (1995
18. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl Acad. Sci. USA 107(17), 7692-7697 (2010
19. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J. 19(13), 3159-3167 (2000
20. Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology (Bethesda) 25(2), 85-101 (2010
21. Lee-Hoeflich ST, Crocker L, Yao E et al. A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy. Cancer Res. 68(14), 5878-5887 (2008
22. Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C, Lupu R. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol. Cancer Res. 1(3), 165-175 (2003
23. Rokicki J, Das PM, Giltnane JM et al. The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Mol. Cancer 9, 150 (2010
24. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366(2), 109-119 (2012
25. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28(7), 1124-1130 (2010
26. Allen LF, Eiseman IA, Fry DW, Lenehan PF. CI-1033, an irreversible pan-ErbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin. Oncol. 30(5 Suppl. 16), 65-78 (2003
27. Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan-ErbB tyrosine kinase inhibitor. Semin. Oncol. 28(5 Suppl. 16), 80-85 (2001
28. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer 8(3), 191-195 (2001
29. Kurokawa H, Lenferink AE, Simpson JF et al. Inhibition of HER2/neu (ErbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 60(20), 5887-5894 (2000
30. Pietras RJ, Arboleda J, Reese DM et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10(12), 2435-2446 (1995
31. Lee H, Jiang F, Wang Q et al. MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol. Endocrinol. 14(11), 1882-1896 (2000
32. Park SS, Kim SW. Activated AKT signaling pathway in invasive ductal carcinoma of the breast: Correlation with HER2 overexpression. Oncol. Rep. 18(1), 139-143 (2007
33. Tokunaga E, Kimura Y, Mashino K et al. Activation of PI3K/AKT signaling and hormone resistance in breast cancer. Breast Cancer 13(2), 137-144 (2006
34. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 9(Suppl. 3), 20-26 (2004
35. Ellis MJ, Tao Y, Young O et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J. Clin. Oncol. 24(19), 3019-3025 (2006
36. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J. Clin. Oncol. 25(5), 486-492 (2007
37. Ejlertsen B, Aldridge J, Nielsen KV et al. Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Ann. Oncol. (2011
38. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer. results from the randomized Phase III TAnDEM study. J. Clin. Oncol. 27(33), 5529-5537 (2009
39. Marcom PK, Isaacs C, Harris L et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res. Treat. 102(1), 43-49 (2007
40. Schwartzberg LS, Franco SX, Florance A, O'Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 15(2), 122-129 (2010
41. Gutierrez MC, Detre S, Johnston S et al. Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 23(11), 2469-2476 (2005
42. Sabnis G, Brodie A. Understanding resistance to endocrine agents: Molecular mechanisms and potential for intervention. Clin. Breast Cancer 10(1), e6-e15 (2010
43. Hurtado A, Holmes KA, Geistlinger TR et al. Regulation of ErbB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456(7222), 663-666 (2008
44. Pancholi S, Lykkesfeldt AE, Hilmi C et al. ErbB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr. Relat. Cancer 15(4), 985-1002 (2008
45. Finn RS, Press M, Dring J et al. Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of lapatinib to letrozole. Biomarker results of EGF30008. Presented at: American Society of Clinical Oncology (ASCO) 45th Annual Meeting. Orlando, FL, USA, 29 May-2 June 2009.
46. Britton DJ, Hutcheson IR, Knowlden JM et al. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res. Treat. 96(2), 131-146 (2006
47. Knowlden JM, Hutcheson IR, Jones HE et al. Elevated levels of epidermal growth factor receptor/c-ErbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144(3), 1032-1044 (2003
48. Jeng MH, Yue W, Eischeid A, Wang JP, Santen RJ. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Res. Treat. 62(3), 167-175 (2000
49. Martin LA, Pancholi S, Chan CM et al. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr. Relat. Cancer 12(4), 1017-1036 (2005
50. Massarweh S, Osborne CK, Creighton CJ et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 68(3), 826-833 (2008
51. McClelland RA, Barrow D, Madden TA et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142(7), 2776-2788 (2001
52. Frogne T, Benjaminsen RV, Sonne-Hansen K et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res. Treat. 114(2), 263-275 (2009
53. Gutierrez MC, Detre S, Johnston S et al. Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 23(11), 2469-2476 (2005
54. Gee JM, Howell A, Gullick WJ et al. Consensus statement. Workshop on therapeutic resistance in breast cancer: Impact of growth factor signalling pathways and implications for future treatment. Endocr. Relat. Cancer 12(Suppl. 1), S1-S7 (2005
55. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl Cancer Inst. 96(12), 926-935 (2004
56. Gee JM, Harper ME, Hutcheson IR et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144(11), 5105-5117 (2003
57. Arpino G, Green SJ, Allred DC et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study. Clin. Cancer Res. 10(17), 5670-5676 (2004
58. Gutteridge E, Agrawal A, Nicholson R, Leung Cheung K, Robertson J, Gee J. The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: A Phase II study. Int. J. Cancer 126(8), 1806-1816 (2010
59. Osborne CK, Neven P, Dirix LY et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: A randomized Phase II study. Clin. Cancer Res. 17(5), 1147-1159 (2011
60. Cristofanilli M, Valero V, Mangalik A et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin. Cancer Res. 16(6), 1904-1914 (2010
61. Polychronis A, Sinnett HD, Hadjiminas D et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled Phase II randomised trial. Lancet Oncol. 6(6), 383-391 (2005
62. Smith IE, Walsh G, Skene A et al. A Phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J. Clin. Oncol. 25(25), 3816-3822 (2007
63. Guix M, Granja Nde M, Meszoely I et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J. Clin. Oncol. 26(6), 897-906 (2008
64. Haddad TC, Yee D. Of mice and (wo)men: Is this any way to test a new drug? J. Clin. Oncol. 26(6), 830-832 (2008
65. Haagenson KK, Wu GS. The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev. 29(1), 143-149 (2010
66. Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: Why some approaches succeed and others fail. Biochem. Pharmacol. 80(5), 624-637 (2010
67. Wu RC, Qin J, Yi P et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol. Cell 15(6), 937-949 (2004
68. Font De Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell. Biol. 20(14), 5041-5047 (2000
69. Cantley LC. The phosphoinositide 3-kinase pathway. Science 296(5573), 1655-1657 (2002
70. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of AKT/PKB by the rictor-mTOR complex. Science 307(5712), 1098-1101 (2005
71. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochim. Biophys. Acta 1697(1-2), 3-16 (2004
72. Carvalho S, Schmitt F. Potential role of PI3K inhibitors in the treatment of breast cancer. Future Oncol. 6(8), 1251-1263 (2010
73. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2(7), 489-501 (2002
74. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann. Surg. Oncol. 15(4), 1064-1069 (2008
75. Lerma E, Catasus L, Gallardo A et al. Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. Virchows Arch. 453(2), 133-139 (2008
76. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin. Cancer Res. 13(2 Pt 1), 408-414 (2007
77. Perez-Tenorio G, Alkhori L, Olsson B et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res. 13(12), 3577-3584 (2007
78. Huang CH, Mandelker D, Gabelli SB, Amzel LM. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle 7(9), 1151-1156 (2008
79. Huang CH, Mandelker D, Schmidt-Kittler O et al. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318(5857), 1744-1748 (2007
80. Mandelker D, Gabelli SB, Schmidt-Kittler O et al. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc. Natl Acad. Sci. USA 106(40), 16996-17001 (2009
81. Miled N, Yan Y, Hon WC et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 317(5835), 239-242 (2007
82. Ellis MJ, Lin L, Crowder R et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res. Treat. 119(2), 379-390 (2010
83. Carpten JD, Faber AL, Horn C et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448(7152), 439-444 (2007
84. Crowder RJ, Phommaly C, Tao Y et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 69(9), 3955-3962 (2009
85. Wu G, Xing M, Mambo E et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 7(5), R609-R616 (2005
86. Myers MP, Pass I, Batty IH et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl Acad. Sci. USA 95(23), 13513-13518 (1998
87. Sanchez CG, Ma CX, Crowder RJ et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 13(2), R21 (2011
88. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br. J. Cancer 86(4), 540-545 (2002
89. Stal O, Perez-Tenorio G, Akerberg L et al. AKT kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res. 5(2), R37-R44 (2003
90. Tokunaga E, Kataoka A, Kimura Y et al. The association between AKT activation and resistance to hormone therapy in metastatic breast cancer. Eur. J. Cancer 42(5), 629-635 (2006
91. Degraffenried LA, Fulcher L, Friedrichs WE, Grunwald V, Ray RB, Hidalgo M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/AKT pathway. Ann. Oncol. 15(10), 1510-1516 (2004
92. Miller TW, Hennessy BT, Gonzalez-Angulo AM et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J. Clin. Invest. 120(7), 2406-2413 (2010
93. Ghayad SE, Bieche I, Vendrell JA et al. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 99(10), 1992-2003 (2008
94. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366(6), 520-529 (2012
95. Bachelot T, Bourgier C, Cropet C et al. TAMRAD: A GINECO randomized Phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Presented at: 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010.
96. Baselga J, Semiglazov V, Van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 27(16), 2630-2637 (2009
97. Chow LWC, Sun Y, Jassem J et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res. Treat. 100(Suppl. 1), S286 (Abstract 6091) (2006
98. Ogita S, Lorusso P. Targeting phosphatidylinositol 3 kinase (PI3K)-AKT beyond rapalogs. Target. Oncol. 6(2), 103-117 (2011
99. Papa V, Gliozzo B, Clark GM et al. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res. 53(16), 3736-3740 (1993
100. Papa V, Pezzino V, Costantino A et al. Elevated insulin receptor content in human breast cancer. J. Clin. Invest. 86(5), 1503-1510 (1990
101. Pandini G, Vigneri R, Costantino A et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Evidence for a second mechanism of IGF-I signaling. Clin. Cancer Res. 5(7), 1935-1944 (1999
102. Shimizu C, Hasegawa T, Tani Y et al. Expression of insulin-like growth factor 1 receptor in primary breast cancer: Immunohistochemical analysis. Hum. Pathol. 35(12), 1537-1542 (2004
103. Peruzzi F, Prisco M, Dews M et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol. Cell. Biol. 19(10), 7203-7215 (1999
104. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl Acad. Sci. USA 90(23), 11217-11221 (1993
105. Buck E, Gokhale PC, Koujak S et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): Rationale for cotargeting IGF-1R and IR in cancer. Mol. Cancer Ther. 9(10), 2652-2664 (2010
106. Lann D, Leroith D. The role of endocrine insulin-like growth factor-I and insulin in breast cancer. J. Mammary Gland Biol. Neoplasia 13(4), 371-379 (2008
107. Fox EM, Miller TW, Balko JM et al. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res. 71(21), 6773-6784 (2011
108. Louvi A, Accili D, Efstratiadis A. Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev. Biol. 189(1), 33-48 (1997
109. Fulzele K, Digirolamo DJ, Liu Z, Xu J, Messina JL, Clemens TL. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J. Biol. Chem. 282(35), 25649-25658 (2007
110. Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res. 67(1), 391-397 (2007
111. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc. Natl Acad. Sci. USA 107(24), 10791-10798 (2010
112. Garofalo C, Manara MC, Nicoletti G et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 30(24), 2730-2740 (2011
113. Buck E, Mulvihill M. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin Investig. Drugs 20(5), 605-621 (2011
114. Baserga R. Customizing the targeting of IGF-1 receptor. Future Oncol. 5(1), 43-50 (2009
115. Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr. Drug Targets 10(10), 923-936 (2009
116. Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther. Targets 12(5), 589-603 (2008
117. Law JH, Habibi G, Hu K et al. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68(24), 10238-10246 (2008
118. Fagan DH, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 13(4), 423-429 (2008
119. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials - early lessons. J. Mammary Gland Biol. Neoplasia 13(4), 471-483 (2008
120. Surmacz E, Bartucci M. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. J. Exp. Clin. Cancer Res. 23(3), 385-394 (2004
121. Zha J, O'Brien C, Savage H et al. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol. Cancer Ther. 8(8), 2110-2121 (2009
122. Foekens JA, Portengen H, Janssen M, Klijn JG. Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer. Cancer 63(11), 2139-2147 (1989
123. Peyrat JP, Bonneterre J, Beuscart R, Djiane J, Demaille A. Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res. 48(22), 6429-6433 (1988
124. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003
125. Yee D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J. Mammary Gland Biol. Neoplasia 5(1), 107-115 (2000
126. Hamelers IHL, Steenbergh PH. Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr. Relat. Cancer 10(2), 331-345 (2003
127. Lee AV, Jackson JG, Gooch JL et al. Enhancement of insulin-like growth factor signaling in human breast cancer. Estrogen regulation of insulin receptor substrate-1expression in vitro and in vivo. Mol. Endocrinol. 13(5), 787-796 (1999
128. Gee JM, Robertson JF, Gutteridge E et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr. Relat. Cancer 12(Suppl. 1), S99-S111 (2005
129. Maor S, Mayer D, Yarden RI et al. Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells. involvement of transcription factor Sp1. J. Endocrinol. 191(3), 605-612 (2006
130. Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J. Biol. Chem. 271(2), 1016-1021 (1996
131. Nickerson T, Huynh H, Pollak M. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem. Biophys. Res. Commun. 237(3), 690-693 (1997
132. Zhang Z, Kumar R, Santen RJ, Song RX. The role of adapter protein Shc in estrogen non-genomic action. Steroids 69(8-9), 523-529 (2004
133. Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D. Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J. Cell. Physiol. 157(2), 229-236 (1993
134. Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. Endocrinology 146(11), 4609-4618 (2005
135. Parisot JP, Hu XF, Deluise M, Zalcberg JR. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br. J. Cancer 79(5-6), 693-700 (1999
136. Santen RJ, Fan P, Zhang Z, Bao Y, Song RXD, Yue W. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids 74(7), 586-594 (2009
137. Song RX, Chen Y, Zhang Z et al. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J. Steroid Biochem. Mol. Biol. 118(4-5), 219-230 (2010
138. Zhang Y, Moerkens M, Ramaiahgari S et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/AKT signaling routes. Breast Cancer Res. 13(3), R52 (2011
139. Kaufman PA, Ferrero JM, Bourgeois H et al. A randomized, double-blind, placebo-controlled, Phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Presented at: 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010.
140. Ryan PD, Neven P, Dirix LY et al. Safety of the anti-IGF-1R antibody CP-751,871 in combination with exemestane in patients with advanced breast cancer. Presented at: San Antonio Breast Cancer Symposium. San antonio, TX, USA, 10-14 December (Abstract 2136) (2008
141. Haugsten EM, Wiedlocha A, Olsnes S, Wesche J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol. Cancer Res. 8(11), 1439-1452 (2010
142. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 60, 1-41 (1993
143. Hynes NE, Dey JH. Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Res. 70(13), 5199-5202 (2010
144. Turner N, Grose R. Fibroblast growth factor signalling: From development to cancer. Nat. Rev. Cancer 10(2), 116-129 (2010
145. Elbauomy Elsheikh S, Green AR, Lambros MB et al. FGFR1 amplification in breast carcinomas: A chromogenic in situ hybridisation analysis. Breast Cancer Res. 9(2), R23 (2007
146. Turner N, Pearson A, Sharpe R et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70(5), 2085-2094 (2010
147. Tomlinson D, Knowles M, Speirs V. Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int. J. Cancer doi:10.1002/ijc.26304 (2011) (Epub ahead of print
148. Meijer D, Sieuwerts AM, Look MP, Van Agthoven T, Foekens JA, Dorssers LC. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr. Relat. Cancer 15(1), 101-111 (2008
149. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13, 513-609 (1997
150. Myoui A, Nishimura R, Williams PJ et al. C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res. 63(16), 5028-5033 (2003
151. Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, Silva CM. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol. Endocrinol. 22(8), 1781-1796 (2008
152. Planas-Silva MD, Bruggeman RD, Grenko RT, Stanley Smith J. Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem. Biophys. Res. Commun. 341(1), 73-81 (2006
153. Hiscox S, Barrett-Lee P, Borley AC, Nicholson RI. Combining Src inhibitors and aromatase inhibitors: A novel strategy for overcoming endocrine resistance and bone loss. Eur. J. Cancer 46(12), 2187-2195 (2010
154. Castoria G, Migliaccio A, Bilancio A et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 20(21), 6050-6059 (2001
155. Song RX, Zhang Z, Santen RJ. Estrogen rapid action via protein complex formation involving ERalpha and Src. Trends Endocrinol. Metab. 16(8), 347-353 (2005
156. Feng W, Webb P, Nguyen P et al. Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway. Mol. Endocrinol. 15(1), 32-45 (2001
157. Shupnik MA. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: Implications for cell proliferation. Oncogene 23(48), 7979-7989 (2004
158. Yue W, Fan P, Wang J, Li Y, Santen RJ. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J. Steroid Biochem. Mol. Biol. 106(1-5), 102-110 (2007
159. Finn RS. Targeting Src in breast cancer. Ann. Oncol. 19(8), 1379-1386 (2008
160. Vallabhaneni S, Nair BC, Cortez V et al. Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res. Treat. 130(2), 377-385 (2011
161. Morgan L, Gee J, Pumford S et al. Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol. Ther. 8(16), 1550-1558 (2009
162. Elsberger B, Paravasthu DM, Tovey SM, Edwards J. Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment. J. Cancer Res. Clin. Oncol. 138(2), 327-332 (2012
163. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res. Treat. 97(3), 263-274 (2006
164. Hiscox S, Jordan NJ, Morgan L, Green TP, Nicholson RI. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin. Exp. Metastasis 24(3), 157-167 (2007
165. Planas-Silva MD, Hamilton KN. Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and
166. Herynk MH, Beyer AR, Cui Y et al. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells. Mol. Cancer Ther. 5(12), 3023-3031 (2006
167. Anbalagan M, Carrier L, Glodowski S, Hangauer D, Shan B, Rowan BG. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor alpha positive breast cancer. Breast Cancer Res. Treat. doi:10.1007/s10549-011-1513-3 (2011) (Epub ahead of print
168. Hiscox S, Jordan NJ, Smith C et al. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res. Treat. 115(1), 57-67 (2009
169. Chen Y, Guggisberg N, Jorda M et al. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin. Cancer Res. 15(10), 3396-3405 (2009
170. Mayer EL, Baurain JF, Sparano J et al. A Phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin. Cancer Res. 17(21), 6897-6904 (2011
171. Pathiraja TN, Stearns V, Oesterreich S. Epigenetic regulation in estrogen receptor positive breast cancer - role in treatment response. J. Mammary Gland Biol. Neoplasia 15(1), 35-47 (2010
172. Brinkman JA, El-Ashry D. ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J. Mammary Gland Biol. Neoplasia 14(1), 67-78 (2009
173. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54(10), 2552-2555 (1994
174. Yan L, Nass SJ, Smith D, Nelson WG, Herman JG, Davidson NE. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol. Ther. 2(5), 552-556 (2003
175. Keen JC, Yan L, Mack KM et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res. Treat. 81(3), 177-186 (2003
176. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res. 61(19), 7025-7029 (2001
177. Zhou Q, Atadja P, Davidson NE. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol. Ther. 6(1), 64-69 (2007
178. Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM. Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res. 71(5), 1893-1903 (2011
179. Fan J, Yin WJ, Lu JS et al. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J. Cancer Res. Clin. Oncol. 134(8), 883-890 (2008
180. Sharma D, Saxena NK, Davidson NE, Vertino PM. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: Tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res. 66(12), 6370-6378 (2006
181. Fan M, Yan PS, Hartman-Frey C et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 66(24), 11954-11966 (2006
182. Munster PN, Thurn KT, Thomas S et al. A Phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br. J. Cancer 104(12), 1828-1835 (2011
183. Yardley DA, Ismail-Khan RR, Klein PM et al. Entinostat, a novel histone deacetylase inhibitor, added to exemestane improves PFS in advanced breast cancer in a randomized, Phase II, double-blind study. Presented at: 34th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 7 December 2011.
184. Andorfer CA, Necela BM, Thompson EA, Perez EA. MicroRNA signatures: Clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol. Med. 17(6), 313-319 (2011
185. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116(2), 281-297 (2004
186. Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc. Natl Acad. Sci. USA 100(17), 9779-9784 (2003
187. Lowery AJ, Miller N, Devaney A et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 11(3), R27 (2009
188. Mattie MD, Benz CC, Bowers J et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer 5, 24 (2006)
189. Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M et al. MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res. Treat. 127(1), 43-51 (2011)